IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how disease is understood, diagnosed and treated, has raised over £40 million in an oversubscribed Series A co-led by IQ Capital and Molten Ventures, with participation from The British Business Bank and Meltwind alongside existing investors. Proceeds will support operational expansion, clinical platform and infrastructure development, and the advancement of IMU Biosciences' clinical programmes.
By combining high-fidelity multi-omic analysis with proprietary machine learning analytics, IMU Biosciences can use a simple blood sample to measure over 100 million immune data points, creating what it describes as the most detailed immune picture ever assembled at clinical scale. The platform is designed to establish a universal standard for immune profiling, enabling the discovery of new immune mechanisms, identifying precision approaches, monitoring disease progression and treatment course, and predicting treatment suitability and efficacy for individual patients. To date, IMU Biosciences has built the world's largest immune dataset, with samples from over 25,000 people and unrivalled access to patient samples and population-wide clinical data.
Having now raised a total of £45 million since inception, IMU Biosciences is expanding its operations as it works to translate its immune profiling platform into clinical practice across the full spectrum of human health and disease. Funding will be used to advance clinical programmes including a Stem Cell Transplant Programme, a Solid Organ Transplant Programme, and MANIFEST, a UK research consortium investigating patient response to cancer immunotherapies.
We are delighted to announce IMU's fundraise, which will allow us to expand our operations and develop our platform whilst continuing to deploy our groundbreaking technology across our clinical programmes as we work to fundamentally change how we understand, diagnose, and treat disease. Despite the immune system's profound importance on all aspects of our health, the system as a whole remains poorly understood - obscured by tools that are fragmented, mechanistic and low-resolution. With the largest immune system dataset globally and proprietary technology, IMU is uniquely positioned to fuel discoveries, devise treatments and empower clinicians; improving outcomes for patients across the full spectrum of human health and disease.
When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could unlock something genuinely transformative in precision medicine. Our participation in this round reflects what we've seen since: a team that executes and a platform that delivers. The immune system sits at the heart of almost every disease; a company that can interrogate it at this resolution has the potential to redefine how we match the right treatment to the right patient at the right time. We're proud to be IMU's largest shareholder and delighted to welcome IQ Capital and the British Business Bank as investors to the round, their support is a further corroboration of what IMU is building. We're excited about what comes next.
We're thrilled to support IMU on the next step in their journey as a co-lead investor within this latest funding round. With the world's largest immune dataset and proprietary machine learning analytics, IMU is pioneering research to realise the huge value of health data, creating better insights for clinicians and improved outcomes for patients. We are proud to be a part of the company's next phase, and are excited to see what the company is able to accomplish as it grows and develops its technology.
IMU represents a rare combination of proprietary data scale and deep biological insight. By generating an unprecedented, high-resolution view of the human immune system, the company is creating a foundational platform with the potential to transform how disease is understood and treated. We are excited to support the team as they scale their platform here in the UK and translate this capability into meaningful impact for patients.
